M C M Melo, A K Silveira, A P R Dalvi, J Silva, V S Printes, L Anselmo, T I da Silva, M M Oliveira, C Conceição, A Lopes, V Bollela, M Cordeiro-Santos, M Bhering, A S R Moreira, A C C Carvalho, A L Kritski
{"title":"Accuracy of Truenat™ MTB Plus for the diagnosis of pulmonary TB.","authors":"M C M Melo, A K Silveira, A P R Dalvi, J Silva, V S Printes, L Anselmo, T I da Silva, M M Oliveira, C Conceição, A Lopes, V Bollela, M Cordeiro-Santos, M Bhering, A S R Moreira, A C C Carvalho, A L Kritski","doi":"10.5588/ijtldopen.24.0561","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Truenat™ is a WHO-recommended rapid molecular test for diagnosing TB and detecting rifampicin resistance, whose performance has been evaluated in a few high TB burden countries.</p><p><strong>Methods: </strong>A prospective multicentre study was conducted in Brazil to estimate the sensitivity and specificity of Truenat MTB Plus compared to Xpert<sup>®</sup> MTB/RIF Ultra for detecting pulmonary TB. Liquid culture for <i>Mycobacterium tuberculosis</i> and drug susceptibility testing were used as reference.</p><p><strong>Results: </strong>Among 283 participants, 112 (39.6%) had culture-positive pulmonary TB. The sensitivity and specificity of Truenat MTB Plus were respectively 72.7% (95% CI 63.41-80.78) and 99.4% (95% CI 96.71-99.98), compared to 78.4% (95% CI 69.56-85.63) and 99.4% (95% CI 96.67-99.98) for Xpert MTB/RIF Ultra. In 89 people living with HIV (PLHIV), Truenat MTB Plus showed a sensitivity of 45.0% (95% CI 23.06-68.47) and specificity of 100.0% (95% CI 95.64-100.00). Among 71 patients previously treated for TB, Truenat MTB Plus showed sensitivity and specificity of respectively 79.3% (95% CI 60.28-92.01) and 97.5% (95% CI 86.84-99.94). Xpert MTB/RIF Ultra detected rifampicin resistance in 11/88 samples (12.5%) vs 9/72 (12.5%) with Truenat MTB Plus.</p><p><strong>Conclusion: </strong>The Truenat MTB Plus performance was comparable to Xpert MTB/RIF Ultra. Both tests demonstrated lower sensitivity in PLHIV.</p>","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 4","pages":"199-207"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984528/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJTLD open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5588/ijtldopen.24.0561","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Truenat™ is a WHO-recommended rapid molecular test for diagnosing TB and detecting rifampicin resistance, whose performance has been evaluated in a few high TB burden countries.
Methods: A prospective multicentre study was conducted in Brazil to estimate the sensitivity and specificity of Truenat MTB Plus compared to Xpert® MTB/RIF Ultra for detecting pulmonary TB. Liquid culture for Mycobacterium tuberculosis and drug susceptibility testing were used as reference.
Results: Among 283 participants, 112 (39.6%) had culture-positive pulmonary TB. The sensitivity and specificity of Truenat MTB Plus were respectively 72.7% (95% CI 63.41-80.78) and 99.4% (95% CI 96.71-99.98), compared to 78.4% (95% CI 69.56-85.63) and 99.4% (95% CI 96.67-99.98) for Xpert MTB/RIF Ultra. In 89 people living with HIV (PLHIV), Truenat MTB Plus showed a sensitivity of 45.0% (95% CI 23.06-68.47) and specificity of 100.0% (95% CI 95.64-100.00). Among 71 patients previously treated for TB, Truenat MTB Plus showed sensitivity and specificity of respectively 79.3% (95% CI 60.28-92.01) and 97.5% (95% CI 86.84-99.94). Xpert MTB/RIF Ultra detected rifampicin resistance in 11/88 samples (12.5%) vs 9/72 (12.5%) with Truenat MTB Plus.
Conclusion: The Truenat MTB Plus performance was comparable to Xpert MTB/RIF Ultra. Both tests demonstrated lower sensitivity in PLHIV.